Dr. Alain Bernard is Chief Technology Officer of VectivBio and brings more than 30 years of experience in bioprocess development to the company.
Prior to joining VectivBio, Dr. Bernard served as Head of Global Biotech Process Development at R-Pharm and Vice President of Biopharmaceutical Process Sciences at UCB. During the 10 years spent at UCB, he oversaw process development for all new chemical and biological entities. He contributed to launching several biotech and small molecules into commercial phases and lifecycle management of marketed products. Prior to UCB, Dr. Bernard served as Director of Biotech Process Development at Merck Serono where he was responsible for the biotechnology process developments that delivered several improved processes for strategic products. He began his career at Biogen, Geneva, a site that was transitioned to the Glaxo-Wellcome Institute of Molecular Biology.
Dr. Bernard earned his Ph.D. in Biochemical Engineering from a joint program between AgroParisTech in France and the Massachusetts Institute of Technology in the U.S.